drugset / Trial / NCT00111553
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
Phase 1
Completed
45 enrolled
Access to Advanced Health Institute (AAHI)
Bill and Melinda Gates Foundation · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult patients with cutaneous leishmaniasis.
Timeline
- Start
- 2004-10
- Primary completion
- —
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leish-111f | Protein / enzyme biologic | 5 ug | — |
| Subject | Leish-111f | Protein / enzyme biologic | 10 ug | — |
| Subject | Leish-111f | Protein / enzyme biologic | 20 ug | — |
| Background | MPL-SE | Other / unclassified | 25 ug | — |